Moderna surges on pre-earnings momentum, Pfizer dips after beating estimates and raising guidance, and Merck drops despite ...

A late-stage melanoma vaccine report that was posted online and quickly pulled is driving a violent repricing in Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, even though its findings looked ...

A vial of the Moderna Covid-19 vaccine and syringes sit prepared at a pop up vaccine clinic at the Jewish Community Center on April 16, 2021 in the Staten Island borough of New York City. Moderna is ...

Moderna will report on Friday, while the SITC meeting will bring fresh cancer-treatment findings from Immunocore and Candel.

While health authorities are reassuring Canadians that it’s safe to mix COVID-19 vaccines doses, some appear to be rejecting Moderna for Pfizer ...

Key TakeawaysModerna stock jumped 13% on Wednesday to a new 52-week high on early multiple myeloma data and an Ebola vaccine recommendation, then gave back 5% on Thursday ahead of Friday’s report.

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. The FDA recently approved updated 2026-2027 COVID-19 vaccines from Moderna, Pfizer-BioNTech, ...

The cases add to a web of high-stakes patent lawsuits filed by biotech companies against Pfizer and Moderna over the mRNA technology used in their COVID vaccines. Spokespeople for Pfizer and Moderna ...

Sen. Ron Johnson, R-Wis., has sent letters to the CEOs of Pfizer and Moderna seeking answers about adverse reactions to the COVID-19 vaccine following a June 28 press conference with affected ...

A federal judge in Delaware on Monday rejected Pfizer , BioNTech and Moderna's requests ​to dismiss patent lawsuits filed against them by Bayer's ‌Monsanto unit over the messenger RNA technology used ...